These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 16871462)

  • 1. Pain therapeutics--SMi's seventh annual conference. 12-13 June 2006, London, UK.
    Harrop S
    IDrugs; 2006 Aug; 9(8):548-50. PubMed ID: 16871462
    [No Abstract]   [Full Text] [Related]  

  • 2. Pain therapeutics--SMi's Ninth Annual Conference 8-9 June 2009, London, UK.
    Kirkham K
    IDrugs; 2009 Aug; 12(8):489-91. PubMed ID: 19629882
    [No Abstract]   [Full Text] [Related]  

  • 3. Nociception: Taking the Pain out of Drug Discovery. 28 November 2006, London, UK.
    Norman P
    IDrugs; 2007 Feb; 10(2):102-5. PubMed ID: 17285460
    [No Abstract]   [Full Text] [Related]  

  • 4. The potential of transient receptor potential vanilloid type 1 channel modulators for the treatment of pain.
    Westaway SM
    J Med Chem; 2007 May; 50(11):2589-96. PubMed ID: 17489570
    [No Abstract]   [Full Text] [Related]  

  • 5. [New analgesics coming. Monoclonal NGF antibody takes the lead].
    Claesson A
    Lakartidningen; 2009 Feb 11-17; 106(7):430-4. PubMed ID: 19350769
    [No Abstract]   [Full Text] [Related]  

  • 6. Cannabinoids in pain management: CB1, CB2 and non-classic receptor ligands.
    Davis MP
    Expert Opin Investig Drugs; 2014 Aug; 23(8):1123-40. PubMed ID: 24836296
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transient receptor potential vanilloid-1 antagonists: a survey of recent patent literature.
    Voight EA; Kort ME
    Expert Opin Ther Pat; 2010 Sep; 20(9):1107-22. PubMed ID: 20586701
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-NGF painkillers back on track?
    Holmes D
    Nat Rev Drug Discov; 2012 Apr; 11(5):337-8. PubMed ID: 22543456
    [No Abstract]   [Full Text] [Related]  

  • 9. COPD: Novel therapeutics and management strategies--SMi's 7th Annual Conference (October 19-20, 2015--London, UK).
    Watt J; Ganapathi P
    Drugs Today (Barc); 2015 Oct; 51(10):613-7. PubMed ID: 26583304
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pain therapeutics-SMi Conference. 11-12 June, 2003, London, UK.
    De la Rue S
    IDrugs; 2003 Jul; 6(7):652-5. PubMed ID: 12906016
    [No Abstract]   [Full Text] [Related]  

  • 11. Clinical development of TRPV1 antagonists: targeting a pivotal point in the pain pathway.
    Gunthorpe MJ; Chizh BA
    Drug Discov Today; 2009 Jan; 14(1-2):56-67. PubMed ID: 19063991
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Trials in CNS--SMi's Seventh Annual Conference. 25-26 November 2008, London, UK.
    Sherwood D
    IDrugs; 2009 Feb; 12(2):84-6. PubMed ID: 19204879
    [No Abstract]   [Full Text] [Related]  

  • 13. Adaptive designs in clinical drug development--SMi's third annual conference. 4-5 February 2009, London, UK.
    Padhiar M
    IDrugs; 2009 Apr; 12(4):230-2. PubMed ID: 19350466
    [No Abstract]   [Full Text] [Related]  

  • 14. Advances in Antiviral Therapeutics--SMi's Second Annual Conference.
    Alger L
    IDrugs; 2005 Jan; 8(1):29-33. PubMed ID: 15650938
    [No Abstract]   [Full Text] [Related]  

  • 15. Therapeutic potential of vanilloid receptor TRPV1 agonists and antagonists as analgesics: Recent advances and setbacks.
    Wong GY; Gavva NR
    Brain Res Rev; 2009 Apr; 60(1):267-77. PubMed ID: 19150372
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current and emerging targets to treat neuropathic pain.
    Butera JA
    J Med Chem; 2007 May; 50(11):2543-6. PubMed ID: 17489576
    [No Abstract]   [Full Text] [Related]  

  • 17. The multiplicity of spinal AA-5-HT anti-nociceptive action in a rat model of neuropathic pain.
    Malek N; Kostrzewa M; Makuch W; Pajak A; Kucharczyk M; Piscitelli F; Przewlocka B; Di Marzo V; Starowicz K
    Pharmacol Res; 2016 Sep; 111():251-263. PubMed ID: 27326920
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug developers reboot anti-NGF pain programmes.
    Mullard A
    Nat Rev Drug Discov; 2015 May; 14(5):297-8. PubMed ID: 25924571
    [No Abstract]   [Full Text] [Related]  

  • 19. [How close are we from achieving the goal of eliminating pain--a channelopathy revealed the origin of pain].
    Han JS
    Sheng Li Ke Xue Jin Zhan; 2007 Jul; 38(3):199-201. PubMed ID: 17882974
    [No Abstract]   [Full Text] [Related]  

  • 20. Future potential and status of selective sodium channel blockers for the treatment of pain.
    Priest BT
    Curr Opin Drug Discov Devel; 2009 Sep; 12(5):682-92. PubMed ID: 19736626
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.